Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca from its 305,000 sq.-ft. manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of the University of Oxford’s adenovirus vector based COVID-19 vaccine candidate, AZD1222. The agreement accelerates the rapid scale-up of capacity over the coming months to support the dedicated production of AZD1222. Catalent will prepare the facility to enable round-the-clock manufacturing schedul...